Incyte (INCY) announced that the European Commission has approved Minjuvi in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy. The EC decision follows the positive opinion received from the European Medicines Agency’s Committee for Medicinal Products for Human Use in November. This marks the second indication for Minjuvi, which was previously approved by the EC in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma. “The EC approval of Minjuvi addresses a critical need, bringing a new, first-of-its-kind, chemotherapy-free option to patients in Europe with relapsed or refractory FL. Historically, FL patients have had limited treatment options in the second-line setting, and we are proud to drive this important advancement for the lymphoma community as we seek to deliver innovative medicines for patients with cancer,” said Bill Meury, President and Chief Executive Officer.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte’s mCALR Monoclonal Antibody Shows Promise Amid Complex Myelofibrosis and Thrombocythemia Treatment Landscape
- Incyte’s Latest Study Completion: A Step Forward in Drug Interaction Insights
- Incyte Board Member Hervé Hoppenot Retires
- Incyte’s Financial Outlook Dims Amidst Challenges with Opzelura and Jakafi
- Incyte presents updated positive data at ASH